Bausch + Lomb Corp's stock has seen minor fluctuations this week amidst some significant company developments.
This week, Bausch + Lomb Corp (BLCO.TO) has experienced a slight uptick in stock performance, with a 1-week change of +0.29%. Despite a small decline of 0.25% on the most recent trading day, the overall year-to-date performance remains positive at +6.85%. Investors are closely watching the company as it navigates through recent news and upcoming financial results.
Advertisement
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.72B
52W high
$25.70
52W low
$19.36
1W change
+0.29%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO · as of Oct 7, 2026
Wall Street analysts forecast BLCO stock price to rise 5.9% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.79
+5.9% Upside
Previously C$25.78 on Oct 5, 2026
Current Price
C$24.35
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
21.6%
Annualized
90-Day Vol
27.2%
Annualized
Trend (90d)
+26.0%
Annualized drift
90d Mean
C$26.72
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$25.11 | C$23.31 – C$27.06 |
| 60 trading days | C$25.90 | C$23.31 – C$28.79 |
| 90 trading days | C$26.72 | C$23.48 – C$30.40 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Bausch + Lomb's recent FDA meeting regarding a novel oral treatment for dry AMD could signal potential growth in its product pipeline. However, the company's financial performance metrics, including a negative profit margin and return on equity, warrant cautious optimism as investors await further clarity from upcoming earnings.
C$24.77
Bausch + Lomb's last close price reflects a stable position within its 52-week range of C$19.36 to C$25.70, indicating a relatively secure trading environment.
Bull case
The recent FDA meeting about a new oral treatment for dry AMD could strengthen Bausch + Lomb's market position and expand its product offerings. This advancement may lead to improved revenue streams in the future.
Bear case
Despite the positive developments, the company's negative profit margin and return on equity raise concerns about its financial health and long-term profitability. These factors could affect investor confidence moving forward.
Recent Price Action
Advertisement
Bausch + Lomb Corp's stock closed at C$24.77, reflecting a small decline of 0.25% in the latest trading session. Over the past week, the stock has gained 0.29%, while it has experienced a decrease of 2.52% over the past month. Year-to-date, Bausch + Lomb has shown a positive performance with a 6.85% increase.
Company News
Several recent developments have impacted Bausch + Lomb's stock performance. Notably, on October 6, the company announced advancements in a novel oral treatment for dry AMD, following a constructive meeting with the FDA. This news suggests potential growth in their product portfolio. Additionally, Bausch + Lomb is set to release its third-quarter financial results on October 28, which will provide further insights into the company's financial health. On October 1, SpyGlass Pharma's acquisition of Advanced Vision Science, Inc. was announced, which could enhance Bausch + Lomb's lens portfolio capabilities.
Technical Picture
From a technical perspective, Bausch + Lomb's stock is currently trading above its 50-day moving average of C$23.87 (+3.8%) and its 200-day moving average of C$23.01 (+7.6%). The stock's 52-week range is between C$19.36 and C$25.70, indicating that it is currently trading at 85% of its range. The stock has a beta of 0.56, suggesting lower volatility compared to the broader market. Notably, the latest trading volume was 2,751 shares, which is 1.87 times the 20-day average volume of 1,186 shares, indicating increased trading activity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
